2nd Annual Biosimilars Summit

The Vonlanthen Group are pleased to invite you to the "2nd Annual Biosimilars Summit" scheduled for the 8th and 9th of February, 2016 in Berlin. This innovative B2B event will enable the participants to learn about the latest trends of the Biosimilars, commercialization aspects, Regulatory advises and strategies for Biosimilars development. As biosimilars are now being developed and manufactured using todays state of the art technology and techniques, they can potentially also offer some benefits, in addition to cost, over the reference biologics. It is proved that biosimilars could save the U.S. health system close to $44 billion in the next ten years.

Key Practical Learning Points of the Summit:

- The latest trends of the Biosimilars

- Successful Commercialization of Biosimilars in Europe and USA

- Biosimilars In Emerging Markets – Regulatory and Commercial Considerations

- Industry Partnerships: Key Success Factor to Win in Biosimilar Space

- Regulatory Advice on Designing Biosimilar Trials

- Totality of Evidence and What It Means to Clinician

- Experience of Global Clinical Biosimilar Trials

- Strategies and competing products for a successful commercialization

Who Should Attend:

Chief Executives, Executive Directors, Vice Presidents, Heads and Team Leaders and Managers including:
 

Biologics/Biotechnology/ Biogenerics;Biopharmaceuticals; Legal Affairs ! Intellectual property; Pricing and Reimbursement; Clinical Immunology; Regulatory Compliance; R&D; Preclinical and Clinical Development; New Product Development; Quality Affairs/ Quality Control; Principal Scientist; Pharmacovigilance

Chief Scientific Officer; Drug Safety & Risk Management; Health Economics; Process Control and Analytical Technologies; Business Development; Commercial Affairs; Marketing & sales; Legislation and Policy Advice; Business Development; Manufacturing; Drug and Safety Assessment; Market Strategy; Regulatory Affairs;